Optimer (OPTR) Announces Add-on Payment From Medicare & Medicaid Services for its DIFICID
- Top 10 News for 8/18 - 8/22: Apple Back to Record Highs; Ballmer Bids Microsoft 'Adieu'; Dollar Store M&A Saga Continues
- Yellen Jackson Hole Speech: Labor Market Dynamics and Monetary Policy
- It's About Time Apple (AAPL) Price Targets Started Moving Higher
- Dynegy (DYN) to Acquire Duke Energy's (DUK) Midwest Generation Assets in $6.25B Deal
- Murata Electronics to Acquire Peregrine Semi (PSMI) in Net $465M Deal
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for DIFICID tablets administered in the inpatient setting to treat Clostridium difficile-associated diarrhea (CDAD). Introduced in 2001, the CMS NTAP program is designed to support timely access of innovative therapies used to treat Medicare beneficiaries in the inpatient setting. The NTAP program is only available to new technologies demonstrating a substantial clinical improvement and meeting specific cost thresholds. The NTAP payment will provide hospitals with a payment, in addition to the standard-of-care DRG reimbursement, of up to 50% of the cost of DIFICID for a period of two to three years, effective in the fiscal year starting on October 1, 2012. For 2013, CMS has assigned a maximum payment of $868.00. The NTAP payment is available to hospitals only for individual patient cases that are more costly than the average DRG charges.
You May Also Be Interested In
- FDA Approves ViiV Healthcare's Triumeq (GSK) (PFE)
- Actavis (ACT) Reports Generic Neupro Patent Challenge
- Aastrom Bio (ASTM) Reports Data from Phase 2a Studies of ixmyelocel-T for DCM
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!